Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PD-1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    424 result(s) found for: PD-1. Displaying page 3 of 22.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-005240-42 Sponsor Protocol Number: CA209-686 Start Date*: 2017-05-31
    Sponsor Name:Oslo University Hospital (OUS)
    Full Title: REPORT; REirradiation and PD-1 blockade On Recurrent squamous cell head and neck Tumors
    Medical condition: Head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002245-18 Sponsor Protocol Number: OMX-0407-101 Start Date*: 2022-11-14
    Sponsor Name:iOmx Therapeutics AG
    Full Title: A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase inhibitor in patients with previously treated unresectable solid tumours
    Medical condition: Previously treated unresectable solid tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004770-10 Sponsor Protocol Number: IBCSG_45-13/BIG_4-13 Start Date*: 2014-09-23
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers
    Medical condition: Patients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy. A parallel cohort of 15 patients wi...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004944-37 Sponsor Protocol Number: MK-3475-054-07 Start Date*: 2015-09-22
    Sponsor Name:Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc
    Full Title: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial o...
    Medical condition: Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-004678-16 Sponsor Protocol Number: INCB24360-207 Start Date*: 2018-05-31
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
    Medical condition: Subjects with solid tumors of the type of colorectal cancer, pancreatic ductal adenocarcinoma, Squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, any solid tumor that pro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001514-42 Sponsor Protocol Number: CA209-040 Start Date*: 2015-01-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I-II Dose Escalation and Expansion Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibod...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 100000004864 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002300-27 Sponsor Protocol Number: SPON1529-16 Start Date*: 2019-09-13
    Sponsor Name:Cardiff University
    Full Title: Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III Squamous Cell Carcinoma of Anus
    Medical condition: Locally advanced (stage IIIA/B, T3/T4, any N,M0) anal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061424 Anal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-005132-33 Sponsor Protocol Number: 73763989PAHPB2008 Start Date*: 2022-04-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)ide Analogs, and a PD-1 inhibitor in Chronic Hepatitis B Pati...
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000931-15 Sponsor Protocol Number: ICR-CTSU/2016/10060 Start Date*: 2018-07-02
    Sponsor Name:Institute of Cancer Research
    Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004522-29 Sponsor Protocol Number: UCL/17/0920 Start Date*: 2019-10-28
    Sponsor Name:University College London
    Full Title: Phase Ib/II trial of Histone Deacetylase Inhibitor CXD101 in combination with Programmed Cell Death Protein-1 Inhibitor Pembrolizumab for relapsed or refractory Diffuse Large B-cell Lymphoma
    Medical condition: Relapsed and refractory Diffuse Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000038-33 Sponsor Protocol Number: DF6002-001 Start Date*: 2021-08-25
    Sponsor Name:Dragonfly Therapeutics, Inc.
    Full Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monoth...
    Medical condition: Solid Tumor Melanoma NSCLC Triple-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003546-16 Sponsor Protocol Number: Debio1143-106 Start Date*: 2019-03-06
    Sponsor Name:Debiopharm International SA
    Full Title: SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial A dose-optimization, exploratory phase Ib/II study to assess...
    Medical condition: Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001879-37 Sponsor Protocol Number: GB1275-1101(KEYNOTE-A36) Start Date*: 2020-01-14
    Sponsor Name:GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.
    Full Title: A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination...
    Medical condition: Phase 1: Advanced solid tumors, metastatic pancreatic adenocarcinoma Phase 2: Specified metastatic solid tumors
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-006331-26 Sponsor Protocol Number: UC-0107/1810 Start Date*: 2022-02-15
    Sponsor Name:UNICANCER
    Full Title: Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alo...
    Medical condition: BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004003-39 Sponsor Protocol Number: 2018-BN-001 Start Date*: 2018-12-19
    Sponsor Name:UZ Brussel
    Full Title: A stratified dual-arm open-label two-stage phase 2 trial of trametinib in patients with advanced pretreated BRAFV600 wild-type melanoma
    Medical condition: ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027150 Melanoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002234-14 Sponsor Protocol Number: OR2805-101 Start Date*: 2023-06-07
    Sponsor Name:OncoResponse, Inc.
    Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
    Medical condition: Solid tumor cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000133-31 Sponsor Protocol Number: AGO/2017/001 Start Date*: 2017-07-31
    Sponsor Name:UZ Gent
    Full Title: Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer: detection of the maximum tolerated dose.
    Medical condition: local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx in previously irradiated tissue, with former irradiation with cu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002325-18 Sponsor Protocol Number: PemDoc Start Date*: 2016-01-29
    Sponsor Name:Med. Univ. Wien
    Full Title: Immunomodulation of pembrolizumab plus docetaxel for the treatment of r/m SCCHN after platinum failure
    Medical condition: head and neck cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002563-22 Sponsor Protocol Number: 2020/538 Start Date*: 2021-09-13
    Sponsor Name:CHU de Besançon
    Full Title: Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study
    Medical condition: metastatic anal canal cancer
    Disease:
    Population Age: Gender:
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001707-32 Sponsor Protocol Number: NIVOPTIMIZE-trial Start Date*: 2021-07-08
    Sponsor Name:Erasmus Medical Center Rotterdam
    Full Title: Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
    Medical condition: Patients with advanced or metastatic melanoma or renal cell carcinoma treated with nivolumab monotherapy in a 480mg or 6 mg/kg 4 weekly scheme (either from start or after combination therapy with i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 11:24:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA